Allogene Therapeutics Statistics
Total Valuation
ALLO has a market cap or net worth of $641.99 million. The enterprise value is $456.15 million.
| Market Cap | 641.99M |
| Enterprise Value | 456.15M |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALLO has 345.15 million shares outstanding. The number of shares has increased by 9.93% in one year.
| Current Share Class | 345.15M |
| Shares Outstanding | 345.15M |
| Shares Change (YoY) | +9.93% |
| Shares Change (QoQ) | +6.31% |
| Owned by Insiders (%) | 4.34% |
| Owned by Institutions (%) | 42.42% |
| Float | 270.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 55,058.96 |
| PB Ratio | 1.63 |
| P/TBV Ratio | 2.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.65, with a Debt / Equity ratio of 0.29.
| Current Ratio | 9.65 |
| Quick Ratio | 9.47 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -153.33 |
Financial Efficiency
Return on equity (ROE) is -52.32% and return on invested capital (ROIC) is -28.14%.
| Return on Equity (ROE) | -52.32% |
| Return on Assets (ROA) | -25.97% |
| Return on Invested Capital (ROIC) | -28.14% |
| Return on Capital Employed (ROCE) | -51.09% |
| Weighted Average Cost of Capital (WACC) | 6.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.14M |
| Employee Count | 152 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.91% in the last 52 weeks. The beta is 0.46, so ALLO's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +40.91% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 1.85 |
| Relative Strength Index (RSI) | 42.33 |
| Average Volume (20 Days) | 9,672,287 |
Short Selling Information
The latest short interest is 63.39 million, so 18.36% of the outstanding shares have been sold short.
| Short Interest | 63.39M |
| Short Previous Month | 48.04M |
| Short % of Shares Out | 18.36% |
| Short % of Float | 23.42% |
| Short Ratio (days to cover) | 6.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | -131.96M |
| Operating Income | -187.83M |
| Pretax Income | -173.76M |
| Net Income | -173.76M |
| EBITDA | -175.71M |
| EBIT | -187.83M |
| Earnings Per Share (EPS) | -$0.77 |
Balance Sheet
The company has $266.89 million in cash and $81.05 million in debt, with a net cash position of $185.84 million or $0.54 per share.
| Cash & Cash Equivalents | 266.89M |
| Total Debt | 81.05M |
| Net Cash | 185.84M |
| Net Cash Per Share | $0.54 |
| Equity (Book Value) | 278.88M |
| Book Value Per Share | 1.14 |
| Working Capital | 244.96M |
Cash Flow
In the last 12 months, operating cash flow was -$109.23 million and capital expenditures -$296,000, giving a free cash flow of -$109.53 million.
| Operating Cash Flow | -109.23M |
| Capital Expenditures | -296,000 |
| Depreciation & Amortization | 12.13M |
| Net Borrowing | n/a |
| Free Cash Flow | -109.53M |
| FCF Per Share | -$0.32 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.93% |
| Shareholder Yield | -9.93% |
| Earnings Yield | -27.07% |
| FCF Yield | -17.06% |
Analyst Forecast
The average price target for ALLO is $9.00, which is 383.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 383.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |